

Executive Change

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company") today announces that following recent Board and management changes¹, Dr Alexandra Andrews will transition from her current position as Chief Executive Officer (CEO) to a new position of Chief Operating Officer (COO), effective immediately.

Chairman of Neurotech International Mr Mark Davies commented "On behalf of the Board, we would like to thank Alex for her commitment to the role of CEO with Neurotech during an important period for the Company, where she guided us through the Phase I/II clinical trial of NTI164 in children with Autism Spectrum Disorder and the subsequent reporting of clinically meaningful data. This saw a period of significant growth and share price appreciation.

"We are pleased Alex will continue with the Company in her new capacity of Chief Operating Officer, where she will be providing key scientific, strategic and management input into Neurotech's manufacturing, intellectual property, pre-clinical research and clinical trial development moving forward."

Following the release of the Company's Phase I/II clinical trial results in paediatric Autism Spectrum Disorder (ASD), which demonstrated excellent safety/tolerability of NTI164 with 93% of patients showing improvement in their symptoms relating to disease severity at 28 days, Neurotech is currently finalising a pivotal Phase II/III clinical trial design to be conducted in Australia.

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Further Information

Dr Thomas Duthy
Investor Relations & Corporate
Development
td@neurotechinternational.com
+61 (0)402 493 727

Mr Mark Davies
Chairman
md@1861capital.com.au
+61 (0)413 137 887

Media:

Amalie Schreurs
White Noise Communications
amalie@whitenoisecomms.com
+61 (0)431 636 033

About Neurotech

Neurotech International Limited (ASX:NTI) is a biopharmaceutical company focused on the development and commercialisation of neurological solutions that improve quality of life. Neurotech is currently conducting a world-first clinical trial to assess the potential application of NTI164 for the treatment of Autism Spectrum Disorder (ASD). Results of Phase I/II indicated that 93% of participants had notable improvements relating to the severity of illness with no serious side effects. The next step will be initiation of Phase II/III of the trial to further assess the long-term safety and efficacy of NTI164, with the potential to lead to drug registration. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

¹ ASX Announcement 16 August 2022 – Consultant appointment and Board Changes

About NTI164

NTI164 is a proprietary drug formulation derived from a unique cannabis strain with low THC (<0.3%) and a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN. NTI164 has been exclusively licenced from Dolce Cann Global (Ltd), for neurological applications globally. Pre-clinical studies have demonstrated a potent anti-proliferative, anti-oxidative, anti-inflammatory and neuro-protective effects in human neuronal and microglial cells. NTI164 is being developed as a therapeutic drug product for a range of neuroinflammatory orphan diseases in children.